Onyx Pharmaceuticals (ONXX) disclosed in a regulatory filing that the National Comprehensive Cancer Network, or NCCN, published an update to its treatment guidelines on March 8. For the treatment of multiple myeloma, the combination of carfilzomib, lendalidomide and dexamethasone was added to the NCCN guidelines under the category “other regimens” as a therapeutic option for patients who are transplant candidates. Additionally, carfilzomib monotherapy, along with several other agents, was added as an NCCN preferred treatment regimen for salvage therapy. Kyprolis, carfilzomib, for Injection is marketed in the United States by Onyx Pharmaceuticals and is approved in the United States for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy. The treatment regimens utilizing carfilzomib described in the NCCN guidelines have not been approved by the FDA and accordingly, Onyx will not be promoting these uses or making any other proactive statement regarding the NCCN action, the company said. The information disclosed regarding the NCCN treatment guidelines is also publicly available from the NCCN and was provided as a convenience to investors, the company added.